ArticleMaterials today. Bio2026
Engineering biomimetic coronary artery equivalents for Kawasaki disease modeling and drug screening.
Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Kawasaki disease (KD) is an acute vasculitis that primarily affects the pediatric population, with coronary artery lesions constituting its most severe clinical sequela. Although investigated for decades, the precise etiology and pathogenesis of this syndrome remain elusive. This critical knowledge gap stems from the absence of robust in vitro platforms capable of accurately recreating the complex pathophysiological dynamics of pediatric coronary arteries. To overcome this challenge, we developed hollow hydrogel fibers using microfluidic coaxial printing, which were then seeded with human coronary artery smooth muscle cells (HCASMCs) and human umbilical vein endothelial cells (HUVECs) to generate a biomimetic coronary artery construct. The physiological responsiveness of the model was validated through stimulation with TNF-α, and a KD-specific pathological model was established by introducing serum from KD patients. Using this biomimetic platform, we evaluated the therapeutic potential of Atorvastatin (ATOR) and the NLRP3 inflammasome inhibitor MCC950, and explored their underlying mechanisms in attenuating vascular inflammation. Overall, this work introduces a structurally relevant in vitro platform that offers new opportunities for studying KD pathogenesis and accelerating the development of targeted therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.